Ceost 60 Mg Tablet (Raloxifene)
Required
About Ceost 60 Mg Tablet (Raloxifene)
Medicine information
- Active ingredient
- Raloxifene
- Indication
- Treatment and prevention of osteoporosis in postmenopausal women; reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk of invasive breast cancer. Raloxifene is not used to treat existing invasive breast cancer or prevent its recurrence.
- Strength
- 60 mg
- Dosage form
- Tablet
- Route
- Oral
Medicine overview
Ceost 60 Mg Tablet is described as a raloxifene product, but the exact Ceost manufacturer and product packaging could not be independently verified from an authoritative product-specific source. Raloxifene is a selective estrogen receptor modulator (SERM). It acts like estrogen in some tissues while blocking estrogen effects in others. Raloxifene 60 mg tablets are used in postmenopausal women for osteoporosis and, in appropriate patients, to reduce the risk of invasive breast cancer.
What it is used for
Raloxifene is used to prevent and treat osteoporosis after menopause by helping maintain bone density and reduce the risk of vertebral fractures. It is also approved to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women considered at high risk for invasive breast cancer. It does not treat established breast cancer and is not indicated to prevent breast cancer recurrence.
How it works
Raloxifene is a selective estrogen receptor modulator (SERM), meaning its effects on estrogen receptors differ between tissues. In bone, it produces estrogen-like effects that reduce bone breakdown and help preserve bone density after menopause. In breast tissue, raloxifene blocks certain estrogen effects. Because some breast cancers depend on estrogen signalling, this action can reduce the risk of developing invasive breast cancer in appropriately selected postmenopausal women.
How it is taken
Raloxifene 60 mg tablets are taken by mouth. The verified prescribing information states that raloxifene 60 mg is taken once daily and may be taken at any time of day, with or without food. Patients being treated for osteoporosis should have adequate calcium and vitamin D intake; supplementation may be recommended when dietary intake is insufficient. Follow the prescribed instructions and do not change or stop treatment without discussing it with the prescriber.
Important warnings
Raloxifene increases the risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism, and must not be used in women with an active or previous venous blood clot. It should be stopped at least 72 hours before and during prolonged immobilization according to prescribing information. A higher risk of death from stroke was observed in a study of postmenopausal women with coronary heart disease or increased coronary risk. Raloxifene is not intended to prevent cardiovascular disease. Systemic estrogen treatment with raloxifene is not recommended, and bile-acid sequestrants such as cholestyramine can substantially reduce raloxifene absorption. Seek urgent medical attention for sudden chest pain, shortness of breath, coughing blood, one-sided leg pain or swelling, or sudden vision changes.
Side effects and monitoring
Common adverse effects include hot flashes, leg cramps, peripheral swelling, flu-like symptoms, joint pain and increased sweating. The most important serious risk is a blood clot in the legs, lungs or retinal veins; stroke-related risk also requires consideration in women with relevant cardiovascular risk factors. Urgent medical assessment is needed for leg swelling or pain, sudden shortness of breath, chest pain, coughing blood or sudden visual changes. Regular breast examinations and mammograms remain necessary when raloxifene is being used to reduce invasive breast cancer risk. Unexplained vaginal bleeding should also be medically evaluated.
Pregnancy
Raloxifene is contraindicated during pregnancy and is not indicated for women who may become pregnant. Exposure during pregnancy may cause fetal harm.
Breastfeeding
Raloxifene is not indicated for use during lactation. There are no adequate data on raloxifene in human milk or its effects on a breastfed child, and its estrogen-modulating action may interfere with normal mammary function during lactation.
Food, drink and interactions
No specific raloxifene–alcohol interaction is established in the cited prescribing information. However, drinking large amounts of alcohol is discouraged as part of osteoporosis management because it can adversely affect bone health.
Food and drink
Raloxifene can be taken with or without food, and no specific food restriction is required by the verified prescribing information. Adequate dietary calcium and vitamin D are important during osteoporosis treatment; supplements may be recommended if dietary intake is insufficient.
Frequently asked questions
Can raloxifene make hot flashes worse?
Yes. Hot flashes are a recognized common side effect of raloxifene and may be more noticeable during the first months of treatment.
Does raloxifene help rebuild bone?
Raloxifene reduces bone breakdown and helps maintain or increase bone density after menopause. Its established osteoporosis benefit includes reducing the risk of vertebral fractures.
Can I take raloxifene with food?
Yes. Raloxifene can be taken with or without food and at any time of day.
Why do I need to worry about blood clots while taking raloxifene?
Raloxifene increases the risk of venous blood clots. Seek urgent medical attention for unexplained leg swelling or pain, sudden chest pain, shortness of breath, coughing blood or sudden vision changes.
Do I need to stop raloxifene before surgery?
Raloxifene prescribing information recommends stopping it at least 72 hours before and during prolonged immobilization because remaining immobile can further increase the risk of blood clots. Follow the instructions of the clinician managing your treatment and surgery.
Can raloxifene be used instead of breast cancer treatment?
No. Raloxifene can reduce the risk of developing invasive breast cancer in certain postmenopausal women, but it is not approved to treat established invasive breast cancer or prevent its recurrence.
Do I still need mammograms while taking raloxifene?
Yes. Raloxifene lowers but does not eliminate the risk of invasive breast cancer, so recommended breast examinations and mammograms should continue.
What should I do if I miss a raloxifene dose?
Take the missed dose when you remember unless it is almost time for the next dose. In that case, skip the missed dose and continue the usual schedule; do not take two doses together.
Sources
Medical information notice: This information does not replace advice from a qualified healthcare professional. Use prescription medicine only as directed by the prescriber and the approved product information.
Related products
Danogen 200 Mg (Danazol)
Evalon 15 gm (Estriol)
Progynon Depot 10 Mg/ 1ml (Estradiol Valerate Injection)
Tocin 80 Mg Injection (Tobramycin)
Reviews
There are no reviews yet.